Opinion
Video
Author(s):
Panelists discuss how continuous subcutaneous apomorphine infusion (CSAI) demonstrates favorable pharmacokinetics compared with other formulations, with the TOLEDO study and its extension showing significant reductions in off time and improvements in motor function with manageable safety profiles.
Video content above is prompted by the following:
CSAI Pharmacokinetics and Clinical Studies
Pharmacokinetics of CSAI vs Other Formulations:
TOLEDO Study Results:
52-Week Open-Label Extension Results:
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.